Abbott Laboratories (ABT) Stock Forecast & Price Target

Abbott Laboratories
Bull Case

Here are some ways that investors could benefit from investing in Abbott Laboratories:

• Abbott Laboratories recently reported positive one-year results for its Amulet 360 Left Atrial Appendage Occluder in the VERITAS study, demonstrating a 98% stroke-free rate and high closure rates for patients with atrial fibrillation, which validates the company's innovation in cardiovascular devices.
• The company delivered strong financial performance in the third quarter of 2026, reporting earnings per share of $1.42 which met analyst consensus, while revenue reached $13.01 billion, representing a 14.5% year-over-year increase that signals robust demand for its healthcare products.
• Abbott Laboratories offers a dividend yield of 2.30% with a quarterly dividend of $0.63 per share, providing a steady income stream for investors, as the company maintains a payout ratio of 94.03% and has a history of reliable dividend payments.
• Institutional investors are showing renewed confidence in the stock, with Rakuten Investment Management Inc. buying a new position of 311,327 shares and Provenance Wealth Advisors LLC increasing its stake by 389.9% in the third quarter, indicating strong professional interest in the company's growth potential.
• The stock is currently trading at $113.43, which is below the consensus price target of $118.32 and the 52-week high of $132.02, suggesting potential for capital appreciation as analysts maintain a Moderate Buy rating with multiple recent upgrades to Buy or Outperform ratings.